{"title":"Many individuals with eating disorders are using GLP-1 medications","authors":"","doi":"10.1002/pu.31498","DOIUrl":null,"url":null,"abstract":"<p>Individuals with eating disorders are using glucagon-like peptide-1 (GLP-1) receptor agonists at a substantially higher rate than the general population, an analysis of an ongoing cross-sectional study has concluded. The analysis found a 32.1% lifetime prevalence of GLP-1 use among adults with an eating disorder.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"37 10","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31498","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Individuals with eating disorders are using glucagon-like peptide-1 (GLP-1) receptor agonists at a substantially higher rate than the general population, an analysis of an ongoing cross-sectional study has concluded. The analysis found a 32.1% lifetime prevalence of GLP-1 use among adults with an eating disorder.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
